319 related articles for article (PubMed ID: 31111881)
1. Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ma C; Panaccione NR; Nguyen TM; Guizzetti L; Parker CE; Hussein IM; Vande Casteele N; Khanna R; Dulai PS; Singh S; Feagan BG; Jairath V
J Crohns Colitis; 2019 Sep; 13(9):1201-1216. PubMed ID: 31111881
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
3. Antibiotics for induction and maintenance of remission in Crohn's disease.
Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
[TBL] [Abstract][Full Text] [Related]
4. Placebo and nocebo responses in randomized controlled trials of Janus kinase inhibitor monotherapy for rheumatoid arthritis : A meta-analysis.
Sung YK; Lee YH
Z Rheumatol; 2022 Jun; 81(5):430-437. PubMed ID: 33687525
[TBL] [Abstract][Full Text] [Related]
5. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
[TBL] [Abstract][Full Text] [Related]
6. Examining the Nocebo Effect in Trials of Neuromodulators for Use in Disorders of Gut-Brain Interaction.
Glissen Brown JR; Sanayei A; Proctor S; Flanagan R; Ballou S; Bain PA; Nee J
Am J Gastroenterol; 2023 Apr; 118(4):692-701. PubMed ID: 36563308
[TBL] [Abstract][Full Text] [Related]
7. Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis.
Barberio B; Savarino EV; Black CJ; Ford AC
Neurogastroenterol Motil; 2022 Jun; 34(6):e14279. PubMed ID: 34672052
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Ullman TA; Ford AC; Abreu MT; Abadir A; Marshall JK; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):661-73. PubMed ID: 21407187
[TBL] [Abstract][Full Text] [Related]
9. Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies.
Bahnam P; Hanzel J; Ma C; Zou L; Narula N; Singh S; Kahan B; Jairath V
J Crohns Colitis; 2023 Apr; 17(3):404-417. PubMed ID: 36219564
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Solitano V; Vuyyuru SK; MacDonald JK; Zayadi A; Parker CE; Narula N; Peyrin-Biroulet L; Danese S; Feagan BG; Singh S; Ma C; Jairath V
J Crohns Colitis; 2023 Nov; 17(11):1800-1816. PubMed ID: 37317532
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
[TBL] [Abstract][Full Text] [Related]
13. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the Placebo and Nocebo effects associated with Placebo treatment in randomized trials of lipid-lowering therapies.
Chin YH; Lim O; Lin C; Chan YY; Kong G; Ng CH; Chong B; Syn N; Chan KE; Muthiah MD; Siddiqui MS; Wang JW; Figtree G; Chan MY; Chew NWS
Eur Heart J Qual Care Clin Outcomes; 2023 Aug; 9(5):511-519. PubMed ID: 36107462
[TBL] [Abstract][Full Text] [Related]
15. Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
Sung YK; Lee YH
Z Rheumatol; 2023 Jan; 82(Suppl 1):59-67. PubMed ID: 34241691
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
Ford AC; Bernstein CN; Khan KJ; Abreu MT; Marshall JK; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):590-9; quiz 600. PubMed ID: 21407179
[TBL] [Abstract][Full Text] [Related]
17. Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials.
Zis P; Mitsikostas DD
J Neurol Sci; 2015 Aug; 355(1-2):94-100. PubMed ID: 26073486
[TBL] [Abstract][Full Text] [Related]
18. Nocebo responses in randomized controlled trials of COVID-19 vaccines.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):5-12. PubMed ID: 34622766
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
20. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
